Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis

Abstract

Serum IL-21 levels in patients with psoriasis are elevated and positively correlate with PASI scores. These results indicate that IL-21 may play an important role in the pathogenesis of psoriasis.

Increased circulating follicular helper T cells and activated B cells correlate with disease severity in patients with psoriasis

“…Furthermore, the levels of ICOS + and ICOS + PD‐1 + TFH cells were shown to correlate with disease severity, suggesting that TFH cells may be involved in the pathogenesis of psoriasis. We also observed that the serum levels of IL‐21 in patients with psoriasis were significantly higher than those in healthy donors, which was shown in a previous study . Moreover, IL‐21 levels positively correlated with the levels of TFH cells and disease severity.…”

Genetic, Epigenetic and Pharmacogenetic Aspects of Psoriasis and Psoriatic Arthritis

“…109,110 IL-21 gene and protein expression is increased in lesional skin of psoriatic patients compared with nonlesional samples, 111 and serum IL-21 levels in patients with psoriasis are increased and positively correlate with Psoriasis Area and Severity Index scores. 112 Although there was a trend toward an association of within the IL-2/ IL-21 region in psoriasis GWAS, 28 strong evidence of association with 2 variants in the IL-2/IL-21 (rs6822844 and rs2069778) region was reported in a subsequent study. 113 In PsA, only 2 genetic loci (ie, IL-12B, TRAF3IP2) involved in Th-17 signaling have reached a genome-wide level of significance.…”

Potential serum biomarkers of treatment response to ustekinumab in patients with psoriasis: a pilot study

“…Considering the cost, it would be expedient to predict the chance of successful treatment before the start of ustekinumab therapy. Studies have focused on alterations in serum proteins during treatment, and have correlated these with the clinical response to systemic treatment including methotrexate and ustekinumab . However, only a limited number of cytokines were studied and no predictors of therapeutic response were found.…”